Main
LBCL, toxicity, aggressive non-Hodgkin lymphoma
PEARLY DISEASE, B CELL LYMPHOMA
Large B cell lymphoma (LBCL), the most common aggressive non-Hodgkin lymphoma (NHL)Standard of care is evolving in the second-line treatment of LBCL and includes traditional salvage chemotherapy followed by consolidation with autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR)-T cell therapy in patients who are transplant ineligible or those with early disease relapse after front-line therapyMosunetuzumab and polatuzumab vedotin have individually shown promising anti-lymphoma activity and manageable toxicity profiles in patients with R/R NHLMosunetuzumab combined with polatuzumab vedotin (mosun-pola) targets distinct components of malignant B cell biology